Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chlorogenic Acid for Injection in Advanced Glioblastoma
NCT02728349Phase 1Completed
- Sponsor
- Sichuan Jiuzhang Biotechnology
- Start
- Apr 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of chlorogenic acid in glioblastoma (GBM), sponsored by Sichuan Jiuzhang Biotechnology. Primary endpoints: Number of adverse events at 30 days, Dose-Limiting Toxicity at 30 days and 3 more. Started Apr 2016; status: completed.
02
Drugs
chlorogenic acid
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02728349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02728349.